PepGen Inc ( PEPG ) shares are trading higher by 125% to $3.09 during Monday’s session after the company announced early data from its FREEDOM-DM1 trial for myotonic dystrophy.

What To Know: PepGen ( PEPG ) on Monday announced promising initial clinical data from its ongoing Phase 1 FREEDOM-DM1 trial evaluating PGN-EDODM1 for myotonic dystrophy type 1. The study showed significant dose-dependent splicing correction, with mean corrections of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.

Read Also: Streaming Stock’s Revenues Quadrupled, But Shares Dropped 35% – Analyst Thinks He Knows Why

The company believes the results surpass previous multi-dose trials and validate its EDO technology's ability to deliver therapeutic oligonucleotides. Safety data were favorable, with mostly mild to moderate adverse events. One serious adverse event of abdominal pain was reported but may have been influenced by an off-label drug.

PepGen ( PEPG ) says the company plans to advance PGN-EDODM1 into multiple-dose studies and expects additional results from the 15 mg/kg cohort in the second half of 2025 and the FREEDOM2 5 mg/kg cohort in early 2026.

Read Also: Unity Software Stock Is Moving Lower Monday: What’s Going On?

According to data from Benzinga Pro, PEPG has a 52-week high of $19.30 and a 52-week low of $1.16.